# IDRX, Inc., a wholly owned subsidiary of GSK, LLC: Phase 1 study closed enrollment, 276 enrolled (Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST))

**Score:** 60/100

| Field | Value |
|---|---|
| Sponsor | IDRX, Inc., a wholly owned subsidiary of GSK, LLC |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors |
| NCT ID | NCT05489237 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumor (GIST); Digestive System Disease; Gastrointestinal Diseases; Metastatic Cancer |
| Intervention types | drug |
| Target enrollment | 276 |
| Site countries | United States, Belgium, China, France, Germany, Italy, Japan, Netherlands, South Korea, Spain, United Kingdom |
| Posted | 2022-08-05 |
| Planned start | 2022-08-03 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-05 |
| Last update posted | 2026-10-05 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- 276 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05489237). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.